Clinical trials: Neoadjuvant Immunotherapy
Cutaneous Squamous Cell Carcinoma
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve…
- Trial name
- NCT06288191
- Testing
- Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melanoma Institute Australia
Hepatocellular Carcinoma, HCC
Neoadjuvant Anti-PD1 in HCC
This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.
- Conditions
- Hepatocellular Carcinoma, HCC, Liver Cancer
- Trial name
- NCT05471674
- Testing
- Nivolumab, Hepatectomy
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Dr Tan-to CHEUNG
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
A phase II, single-arm, open-label study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with PD-(L)1 inhibitor in stage I-IIIB NSCLC adult patients followed by adjuvant…
- Trial name
- NCT04941417
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Immunotherapy
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Trial name
- NCT05479240
- Testing
- Tislelizumab, Capecitabine, oxaliplatin
- Volunteers
- 94 people
- Sponsor
- Fujian Cancer Hospital
NSCLC, Neoadjuvant Therapy
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
This is a randomized, open-label, multicenter phase II study. The trial plans to enroll 164 subjects with resectable stage IIA-IIIB (N2) NSCLC.
- Conditions
- NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
- Trial name
- NEOINSPIRE (NCT07086326)
- Testing
- Ivonescimab+Chemo, Penpulimab+Chemo
- Where
- 5 sites in China
- Volunteers
- 164 people
- Sponsor
- Yang Fan, MD
Rectal Cancer
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
The goal of this clinical trial is to evaluating the efficacy and safety of radiotherapy combined with Tislelizumab, Liposomal Irinotecan, and Capecitabine in patients with locally advanced mid-lower rectal cancer with pMMR..
- Trial name
- NCT07104604
- Testing
- Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
Colorectal Cancer
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic…
- Trial name
- FOBECAMS (NCT06176885)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- yue junhan
Head and Neck Cancer
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Head and neck cancer is the malignant tumor with the highest morbidity and mortality, of which 60% present with locally advanced disease at initial diagnosis, and the 5-year survival rate of standard treatment is less than 30%.
- Trial name
- NCT06208826
- Testing
- Toripalimab, Radiation Therapy, Cisplatin
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
TPF, Immunotherapy
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NPC is one of the most common malignant tumors in the head and neck region of China. Currently, the main treatment regimen for LA-NPC is radical concurrent chemoradiotherapy combined with induction or adjuvant chemotherapy.
- Conditions
- TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
- Trial name
- NCT06781112
- Testing
- albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Weiwei Zhang
Rectal Cancer, Rectal Adenocarcinoma
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between arm A and arm B. The principal research question is whether the addition of durvalumab to FOLFOX chemotherapy and radiation treatment…
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms
- Trial name
- PRIME-RT (NCT04621370)
- Testing
- Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A)
- Volunteers
- 48 people
- Sponsor
- Liz-Anne Lewsley
HR+HER2- Breast Cancer
Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer
For the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) subtype of breast cancer, although surgical, radiotherapy, and endocrine treatments have shown better survival, this subtype has a…
- Trial name
- NCT06639672
- Testing
- Chemotherapy+PD-1 inhibitor+8Gy x 3f, Chemotherapy+PD-1 inhibitor+16Gy x 1f, Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
- Volunteers
- 60 people
- Sponsor
- Lei Liu
Cutaneous Squamous Cell Carcinoma (CSCC)
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
The goal of this clinical trial is to evaluate if short-course radiation therapy (SCRT) can effectively treat high-risk cutaneous squamous cell carcinoma (cSCC) and if active surveillance is a safe alternative to radiation for…
- Trial name
- MOHSAHRTSS (NCT06998342)
- Testing
- Short course radiation, Active Surveillance
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Early Low Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
The study evaluates the combination of immunotherapy of PD-1 antibody and neoadjuvant short-course radiotherapy in early low rectal cancer.
- Trial name
- TORCH-E (NCT05555888)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cervical Carcinoma
Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)
We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.
- Trial name
- NEOLYNC (NCT07653503)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Anaplastic Thyroid Cancer, Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF…
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
- Trial name
- NEO-COMBATXL (NCT06902376)
- Testing
- Cemiplimab, XL092
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Adenocarcinoma
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer.
- Trial name
- NCT06798376
- Testing
- 2-4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, 5-8 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, Gastrectomy
- Where
- China
- Volunteers
- 409 people
- Sponsor
- Chinese PLA General Hospital
Rectal Cancer
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally…
- Trial name
- TRIUNITE-03 (NCT06718543)
- Testing
- AK112 with SCRT and CapeOX, AK112 with SCRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- fan li
Prostate Cancer
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Background: The immune system is the cells and organs in the body that recognize and fight infection and cancer. The prostate specific antigen (PSA)/TRICOM (PROSTVAC) vaccine might teach the immune system to find and kill certain…
- Trial name
- NCT02933255
- Testing
- PROSTVAC-V/F, Nivolumab, Prostatectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Non-comparative Phase II Clinical Trial of Becotatug Vedotin Combined with or without Immune Checkpoint Inhibitors (Penpulimab/Ivonescimab) in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck…
- Trial name
- NCT07381075
- Testing
- Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- West China Hospital